ALDX (Aldeyra Therapeutics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by ALDX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-11 | Nancy Miller-Rich | Director | A | — | — |
| 2026-06-11 | Neal Walker | Director | A | — | — |
| 2026-06-11 | Ben Bronstein | Director | A | — | — |
| 2026-06-11 | RICHARD DOUGLAS | Director | A | — | — |
| 2026-06-11 | Gary M. Phillips | Director | A | — | — |
| 2026-06-11 | William D Clark | Director | A | — | — |
| 2026-06-11 | DARLENE M DEPTULA-HICKS | Director | A | — | — |
| 2026-06-05 | Todd C Brady | President and CEO | Buy | — | — |
| 2026-03-20 | RICHARD DOUGLAS | Director | Buy | — | — |
| 2026-03-19 | Michael Alfieri | Principal Financial Officer | Buy | — | — |
| 2025-08-15 | Michael Alfieri | Principal Financial Officer | Buy | — | — |
| 2025-08-13 | Stephen Machatha | Chief Development Officer | Sell | — | — |
| 2025-06-12 | Neal Walker | Director | A | — | — |
| 2025-06-12 | RICHARD DOUGLAS | Director | A | — | — |
| 2025-06-12 | Nancy Miller-Rich | Director | A | — | — |
| 2025-06-12 | Gary M. Phillips | Director | A | — | — |
| 2025-06-12 | Ben Bronstein | Director | A | — | — |
| 2025-06-12 | MARTIN JOSEPH JOYCE | Director | A | — | — |
| 2025-04-18 | William D Clark | Director | A | — | — |
| 2025-04-07 | JOSEPH EDELMAN | 10%+ Owner | Sell | — | — |
| 2025-03-06 | Stephen Machatha | Chief Development Officer | A | — | — |
| 2025-03-06 | Todd C Brady | President and CEO | A | — | — |
| 2024-10-21 | Nancy Miller-Rich | Director | Buy | — | — |
| 2024-08-14 | Stephen Machatha | Chief Development Officer | Sell | — | — |
| 2024-08-14 | Bruce Greenberg | See Remarks | Sell | — | — |
| 2024-06-06 | MARTIN JOSEPH JOYCE | Director | A | — | — |
| 2024-06-06 | Ben Bronstein | Director | A | — | — |
| 2024-06-06 | Neal Walker | Director | A | — | — |
| 2024-06-06 | Gary M. Phillips | Director | A | — | — |
| 2024-06-06 | RICHARD DOUGLAS | Director | A | — | — |
| 2024-06-06 | Nancy Miller-Rich | Director | A | — | — |
| 2024-04-17 | Bruce Greenberg | See Remarks | Sell | — | — |
| 2024-04-17 | Stephen Machatha | Chief Development Officer | Sell | — | — |
| 2024-04-08 | JOSEPH EDELMAN | 10%+ Owner | Buy | — | — |
| 2024-04-03 | JOSEPH EDELMAN | 10%+ Owner | Buy | — | — |
| 2024-03-12 | Bruce Greenberg | See Remarks | Sell | — | — |
| 2024-03-12 | Stephen Machatha | Chief Development Officer | Sell | — | — |
| 2024-03-12 | Todd C Brady | President and CEO | Sell | — | — |
| 2023-10-18 | JOSEPH EDELMAN | 10%+ Owner | Sell | — | — |
| 2023-09-11 | Gary M. Phillips | Director | M | — | — |
| 2023-09-11 | Todd C Brady | President and CEO | MIXED | — | — |
| 2023-08-24 | Neal Walker | Director | M | — | — |
| 2023-07-05 | Nancy Miller-Rich | Director | A | — | — |
| 2023-07-05 | Gary M. Phillips | Director | A | — | — |
| 2023-07-05 | RICHARD DOUGLAS | Director | A | — | — |
| 2023-07-05 | MARTIN JOSEPH JOYCE | Director | A | — | — |
| 2023-07-05 | Ben Bronstein | Director | A | — | — |
| 2023-07-05 | Neal Walker | Director | A | — | — |
| 2023-06-29 | Ben Bronstein | Director | M | — | — |
| 2023-03-02 | Bruce Greenberg | See Remarks | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 10,801,985 | — |
| — | 10%+ Owner | 10,023,271 | — |
| — | 10%+ Owner | 5,875,851 | — |
| — | Director | 1,877,091 | — |
| — | President and CEO | 1,721,298 | — |
| — | Chief Financial Officer | 274,825 | — |
| — | Chief Commercial Officer | 255,183 | — |
| — | Chief Development Officer | 222,010 | — |
| — | Director | 195,000 | — |
| — | See Remarks | 126,382 | — |
| — | Director | 28,248 | — |
| — | Director | 23,967 | — |
| — | Chief Medical Officer | 17,878 | — |
| — | Director | 15,854 | — |
| — | Director | 15,500 | — |
| — | Director | 14,812 | — |
| — | Principal Financial Officer | 7,500 | — |
| — | Chief Financial Officer | 5,410 | — |
| — | Director | 413 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALDX quote page; the site-wide leaderboard is on the insider transactions hub.